



# BE Studies - Index



**(Sample Document will provide on request)**

**3.0 TABLE OF CONTENTS:**

Sr. No.	CONTENTS	
1.0	TITLE PAGE	
2.0	SYNOPSIS	
3.0	TABLE OF CONTENTS	
4.0	LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS	
5.0	ETHICS	
	5.1	Independent Ethics Committee IEC
	5.2	Ethical Conduct of Study
	5.3	Subject Information and Consent
6.0	Investigators And Study Administrative Structure	
	6.1	Clinical, Analytical and Statistical Facility
7.0	INTRODUCTION	
8.0	STUDY OBJECTIVES	
9.0	INVESTIGATIONAL PLAN	
	9.1	Overall Study Design and Plan: Description
	9.2	Discussion of Study Design
	9.3	Selection of Study Population
	9.3.1	Inclusion Criteria
	9.3.2	Exclusion Criteria
	9.3.3	Removal of Subjects From Study
	9.4	Treatments
	9.4.1	Treatments Administered
	9.4.2	Identity of Investigational Product(s)
	9.4.3	Method of Assigning Subjects to Treatment Group
	9.4.4	Selection of Doses in the Study



Sr. No.	CONTENTS	
	9.4.5	Selection and Timing of Dose for each subject
	9.4.6	Blinding
	9.4.7	Prior and Concomitant Therapy
	9.4.8	Treatment Compliance
	9.5	Pharmacokinetic and Safety Variables
	9.5.1	Pharmacokinetic and Safety Measurements Assessed and Flow Chart
	9.5.2	Appropriateness of Measurements
	9.5.3	Primary Pharmacokinetic Variable(s)
	9.5.4	Drug Concentration Measurements
	9.6	Data Quality Assurance
	9.7	Statistical Methods Planned in the Protocol and Determination of Sample Size
	9.7.1	Statistical and Analytical Plans
	9.7.2	Determination of Sample Size
	9.8	Changes in the Conduct of the Study or Planned Analysis
10.0	STUDY SUBJECTS	
	10.1	Disposition of Subjects
	10.2	Protocol Deviations
11.0	PHARMACOKINETIC EVALUATION	
	11.1	Data Sets Analyzed
	11.2	Demographic and Other Baseline Characteristics
	11.3	Measurements of Treatment Compliance
	11.4	Results and Tabulations of Individual Subject Data
	11.4.1	Analysis of Results
	11.4.2	Statistical and Analytical Considerations
		11.4.2.1 Adjustments for Covariates
		11.4.2.2 Handling of Dropouts / Missing Data
		11.4.2.3 Interim Analysis and Data Monitoring
		11.4.2.4 Multicenter Studies



Sr. No.	CONTENTS		
		11.4.2.5	Multiple Comparisons
		11.4.2.6	Use of a “Standby Subset” of Subjects
		11.4.2.7	Active Control Studies Intended to Show equivalence
		11.4.2.8	Examination of Subgroups
		11.4.3	Tabulation of Individual Subject Vital Sign Data
		11.4.4	Drug Dose, Drug Concentration and Relationship
		11.4.5	Drug-Drug, Drug-Disease Interactions
		11.4.6	By-Subject Displays
		11.4.7	Conclusions
12.0		SAFETY EVALUATION	
	12.1	Extent of Exposure	
	12.2	Adverse Events	
		12.2.1	Brief Summary of Adverse Events
		12.2.2	Display of Adverse Events
		12.2.3	Analysis of Adverse Events
		12.2.4	Listing of Adverse Events by Subject
	12.3	Serious Adverse Events and Other Significant Adverse Events	
		12.3.1	Listing of Serious Adverse Events and Other Significant Adverse Events
		12.3.2	Narratives of Serious Adverse Events and Certain Other Significant Adverse Events
		12.3.3	Analysis & Discussion of Serious Adverse Events & Other Significant Adverse Events
	12.4	Clinical Laboratory Evaluation	
		12.4.1	Listing of Individual Laboratory Measurements By Subject and Each Abnormal Laboratory Value
		12.4.2	Evaluation of Each Laboratory Parameter
		12.4.2.1	Laboratory Values Over Time
		12.4.2.2	Individual Subject Changes
		12.4.2.3	Individual Clinically Significant Abnormalities
	12.5	Vital Signs, Physical Findings and other Observations Related to Safety	



Sr. No.	CONTENTS	
	12.6	Safety Conclusions
13.0		DISCUSSION AND OVERALL CONCLUSIONS
14.0		TABLES, FIGURES, AND GRAPHS REFERRED TO BUT NOT INCLUDED IN THE TEXT
	14.1	Demographic Data Summary Figures and Tables
	14.1.1	Mean Demographic Data of All Subjects (N=36) Included in the Statistical Analysis of the Study
	14.1.2	Composition of Meal Used in Fed Bioequivalence Study
	14.2	Pharmacokinetic Data Summary Figures and Tables
	14.3	Safety Data Summary Figures and Tables
	14.3.1	Display of Adverse Events
	14.3.2	Listing of Deaths, Other Serious and Significant Adverse Events
	14.3.3	Narratives of Deaths, Other Serious and Certain Other Significant Adverse
	14.3.4	Abnormal Laboratory Value Listing (Each Subject)
15.0		REFERENCE LIST
16.0		APPENDICES